Dyslipidemia in HF should continue to be managed according to ApoB-driven, guideline-directed lipid-lowering strategies, including statins and ezetimibe when indicated, while maintaining SGLT2 inhibitors for their established cardiorenal benefit [21,32,34,39-43]. This evidence concerns the gene SLC5A2 and hydrops fetalis.